Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome

NO_LONGER_AVAILABLE

Conditions studied: Lambert-Eaton Myasthenic Syndrome

In brief

Compassionate use of orphan drug 3,4-Diaminopyridine(DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP is used to decrease the muscle weakness associated with LEMS and hopefully will decrease the need for prednisone and all other therapies that were previously required to control symptoms. How long a patient will take 3,4 DAP depends upon if he/she is seeing benefits from the medication or experiencing side effects that will prevent them from continuation in the study.

Key facts

Study ID: NCT01373333
Run by: The Cleveland Clinic
Starts: 1997-09-01
Last updated by the study team: 2016-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Clinical diagnosis of LEMS with or without any of the following: evidence of underlying malignancy, presence of P/Q or N-type calcium channel antibodies, electrodiagnostic evidence of a presynaptic defect of neuromuscular junction transmission.None of these laboratory findings are required for inclusion in this study.
P/Q and N type calcium channel antibodies are measured in the blood as a routine laboratory test during the course of initial diagnosis, but 10-20% of patients with LEMS do not have elevated levels of these antibodies.

You may not qualify if…

Hypersensitivity to any component of this medication.
History of past or current seizures.
History of asthma.
Evidence of prolonged QT syndrome. There is no absolute upper limit of normal for the QTc interval.
Family history of prolonged QTc syndrome, history of unexplained syncope, seizures or cardiac arrest.

Where it is running

Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.